Spyre Therapeutics (FRA:3920) 12-1 Month Momentum % : N/A% (As of Jun. 07, 2024)

Competitive Comparison of Spyre Therapeutics's 12-1 Month Momentum %

For the Biotechnology subindustry, Spyre Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spyre Therapeutics's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Spyre Therapeutics's 12-1 Month Momentum % falls into.

Spyre Therapeutics  (FRA:3920) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spyre Therapeutics  (FRA:3920) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Spyre Therapeutics 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Spyre Therapeutics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Spyre Therapeutics (FRA:3920) Business Description